STOCK TITAN

Edwards Lifesciences (EW) DEF 14A Filings

EW NYSE

Here are the DEF 14A proxy statements from Edwards Lifesciences Corp (EW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow EW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EW filings page.

Rhea-AI Summary

Edwards Lifesciences Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 7, 2026. Holders of common stock as of March 10, 2026 can vote online, by phone, mail, or during the webcast.

Stockholders will elect nine directors for one-year terms, cast an advisory vote on named executive officer pay, ratify PricewaterhouseCoopers LLP as independent auditor for 2026, and approve an amended and restated Long-Term Stock Incentive Compensation Program. The board, led by an independent chair, recommends voting “FOR” all four proposals.

The company highlights 2025 sales of $6.1 billion, up 11.5% on an underlying basis, and more than $1 billion invested in research and development across TAVR, TMTT and Surgical therapies. Annual cash incentives funded at 127% of target, while 2022 performance-based RSUs tied to three-year relative total shareholder return did not vest. Edwards emphasizes strong governance features, including majority voting for directors, proxy access, no poison pill, robust stock ownership guidelines and an executive pay program where a high proportion of compensation is performance-based.